CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 164 enrolled
Drug / intervention
T-DM1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02326974
NCT02326974Phase 2Active
CompareCT.gov

The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting

Dana-Farber Cancer Institute·interventional·Posted Dec 30, 2014·Updated Apr 17, 2026

In Brief

A Phase 2 clinical trial evaluating T-DM1, Pertuzumab, and 1 other intervention for HER-2 Positive Breast Cancer and 3 related conditions. Active but no longer recruiting, targeting 164 participants across 4 sites.

Detailed Summary

This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2Active
20152016201720182019202020212022202320242025202620272028
First PostedDec 30, 2014
Enrollment StartJan 1, 2015
Primary CompletionJun 1, 2018
Study CompletionJan 1, 2028
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.5 years ago

Interventions

T-DM1drug

Neoadjuvant treatment is for a total of 18 weeks.

Pertuzumabdrug

Neoadjuvant treatment is for a total of 18 weeks.

Excision of tumor/mastectomyprocedure

Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.